Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients

Journal of Clinical Virology

Volumn 57, Issue 1, 2013, Pages 50-53

  Lautenschlager, Irmeli ^a   Loginov, Raisa ^a   Mäkisalo, Heikki ^a   Höckerstedt, Krister ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

CMV; Ganciclovir; Liver transplantation; Preemptive therapy; Valganciclovir

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FOLLOW UP; GRAFT RECIPIENT; HUMAN; LIVER GRAFT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA; VIRUS LOAD;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; LIVER TRANSPLANTATION; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84875809117     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.01.013     Document Type: Article

References (20)

1. Razonable R.R. Cytomegalovirus infection after liver transplantation: current concepts and challenges, Review. World J Gastroenterol 2008, 14:4849-4860.
2. Lautenschlager I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Review Transplant Int 2009, 22:1031-1040.
3. Levitsky J., Singh N., Wagener M.M., Stosor V., Abecassis M., Ison M.G. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008, 8:158-161.
4. Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. J Clin Virol 2006, 35:474-477.
5. Kotton C.N., Kumar D., Caliendo A.M., åsberg A., Chou S., Snydman D.R., et al. On behalf of The Transplantation Society International CMV Consensus Group, International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779-795.
6. Baldanti F., Lilleri D., Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 2008, 41:237-241.
7. Vandercasteele E., De Waele J., Vandjick D., Blot S., Vogelaers D., Roxgiers X., et al. Antimicrobial prophylaxis in liver transplant patients - a multicenter survey endorsed by the European Liver and Intestine Transplant Association. Transplant Int 2010, 23:182-190.
8. Emery V.C., Asher K., Sanjuan Cde J. Importance of the cytomegalovirus seropositive recipients as a contributor to disease burden after solid organ transplantation. J Clin Virol 2012, 54:125-129.
9. Sun H.Y., Cacciarelli T.V., Wagener M.M., Singh N. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients. Transplant Immunol 2010, 23:166-169.
10. Atabani S.F., Smith C., Atkinson C., Aldridge R.W., Rodriguez-Perálvarez M., Rolando N., et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012, 12:2457-2464.
11. Piiparinen H., Höckerstedt K., Grönhagen-Riska C., Lautenschlager I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant recipients. J Clin Virol 2004, 30:258-266.
12. Humar A., Gregson D., Caliendo A.M., McGreer A., Malkan G., Krajden M., et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant patients. Transplantation 1999, 68:1305-1311.
13. Eid A.J., Athurs S.K., Deziel P.J., Wilhelm M.P., Razonable R.R. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008, 22:162-170.
14. Bodro M., Sabe N., Lladó L., Baliellas C., Niubó J., Castellotte J., et al. Prophylaxis vs. preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transplant 2012, 18:1093-1099.
15. Lautenschlager I., Halme L., Höckerstedt K., Krogerus L., Taskinen E. Cytomegalovirus infection of the liver transplant; virological, histological, immunological, and clinical observations. Transplant Infect Dis 2006, 8:21-30.
16. Scott M.G., Naing Z., Pavlovic J., Iwasenko J.M., Angus P., Jones R., et al. Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients. J Clin Virol 2011, 51:225-229.
17. Freyer J.F., Heath A.B., Anderson R., Minor P.D., The Collaborative Study Group Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus for nucleic acid amplification-based assays 2010, WHO/BS/10.2138, Geneva, Switzerland, pp. 1-40, 18-22 October.
18. Neil D.A., Hubscher S.G. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology 2002, 35:639-651.
19. Isoniemi H., Höckerstedt K. Helsinki Liver Transplant Registry 2008.
20. Gerna G., Lilleri D., Chiesa A., Zelini P., Furione M., Comolli G., et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid organ transplantation. Am J Transplant 2011, 11:2463-2471.